Introduction 

Understanding Bispecific Antibodies 

        Bispecific Antibodies or CAR T-cell Therapy?

Eligibility and Administration

        Treatment Administration

        Step-Up Dosing Explained

        Transferring Care

        Do I Need A Caregiver to Receive Bispecifics? 

       Early Access Programs

Treatment Course

        Duration of Treatment

Side Effects of Bispecific Antibodies

        General Safety Profile

        Infection Risk (1/3)

        Infection Risk (2/3)

        Infection Risk (3/3)

        Cytokine Release Syndrome (1/4)

        Cytokine Release Syndrome (2/4)

        Cytokine Release Syndrome (3/4)

        Cytokine Release Syndrome (4/4)

        Neurotoxicity and ICANS (1/2)

        Neurotoxicity and ICANS (2/2)

        Low Blood Cell Counts 

        T-cell Exhaustion 

        Teclistamab Side Effect Profile 

        Elranatamab Side Effect Profile 

        Talquetamab Side Effect Profile 

Side Effect Management and Support

        CRS Prevention

        ICANS Prevention

        Infection Prevention (1/4)

        Infection Prevention (2/4)

        Infection Prevention (3/4)

        Infection Prevention (4/4)

        Keep Your Healthcare Team Informed

        Quality of Life Impact

FDA Approved Bispecific Antibodies 

        Teclistamab (TECVAYLI)

        Elranatamab (ELREXFIO)

        Talquetamab (TALVEY)

Bispecific Antibodies in Clinical Trials

        Bispecific Antibodies Clinical Trials

        Linvoseltamab (Regeneron)

        ABBV-383 (Abbvie)

        Alnuctamab (BMS)

        Cevostamab (Genentech)

Treatment Strategies with Bispecific Antibodies

        Bispecific Combinations (1/2)

        Bispecific Combinations (2/2)

        Immunotherapy Treatment Sequencing (1/3)

        Immunotherapy Treatment Sequencing (2/3)

        Immunotherapy Treatment Sequencing (3/3)

        Bispecifics for Newly Diagnosed Myeloma

        Bispecifics in High-Risk Myeloma

        Relapse on Bispecific Antibody Therapy 

        Refractory to Bispecific Antibody Therapy

Caregiver Role in Bispecific Antibody Therapy

Financial Resources for Bispecific Antibody Therapy 

        Pharmaceutical Support Resources

        HealthTree Financial Resources

Future Considerations of Bispecific Antibody Therapy

        Eliminating Disparities

        Bispecifics in the Real World

Share Your Experience

Questions to Ask Your Doctor about Bispecific Antibody Therapy

Additional Resources

        HealthTree Resources

        External References